Red Journal Podcast April 1, 2025: Oligometastatic Head and Neck Cancer - Rationale for Upfront SABR
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Red Journal Podcast April 1, 2025: Oligometastatic Head and Neck Cancer - Rationale for Upfront SABR
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Send us a text
Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.